Panacea Biotec has inked a pact with UNICEF for the supply of Pentavalent Vaccine (Easyfive-TT) in the current year. The company has also received a notification from Pan American Health Organisation (PAHO) for the purchase of Easyfive-TT vaccine in the event the agency should have any requirements through December, 31, 2019.

Besides, the company has received approval from the US health regulator to market a generic version of Merck & Co's Maxalt-MLT tablets, used in treating migraine, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market its generic product to treat migraine in strengths of 5 and 10 mg. The company recently got approval for its anti-cancer formulation facility from USFDA in November 2016.